Differential expression of histone post-translational modifications in acute myeloid and chronic lymphocytic leukemia determined by high-pressure liquid chromatography and mass spectrometry

被引:56
作者
Zhang, LW
Freitas, MA
Wickham, J
Parthun, MR
Klisovic, MI
Marcucci, G
Byrd, JC
机构
[1] Ohio State Univ, Dept Chem, Columbus, OH 43210 USA
[2] Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Internal Med, Div Hematol Oncol, Columbus, OH 43210 USA
关键词
D O I
10.1016/j.jasms.2003.10.001
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The post-translational modification of the core histones is critical to the regulation of chromatin structure. Traditional methods for the determination of histone modification utilize immunoassay techniques to determine the extent and site of post-translational modification. These methods, though sensitive, require site-specific antibodies. This manuscript describes the application of reverse-phase high-pressure liquid chromatography and mass spectrometry (LC-MS) to analyze global modification levels of core histones. The method is fast, sensitive, and easily automated. Furthermore, the technique gives the global patterns of modification for all four core histones in a single experiment. The LC-MS method was optimized using histones extracted from bovine thymus. These methods were then applied to the characterization of changes in histone modification in acute myeloid leukemia (AML) cell lines treated with histone deacetylase (HDAC) inhibitors. Dose-dependent changes in the distribution of modified core histones were observed. These results were validated in primary leukemia cells from patients with refractory or relapsed AML or chronic lymphocytic leukemia (CLL) treated on a Phase I clinical trial of the HDAC inhibitor depsipeptide. An increase in the relative abundance of specific acetylated forms of histone H4 was readily observable in these patients at intervals of 4 and 24 h after treatment.
引用
收藏
页码:77 / 86
页数:10
相关论文
共 47 条
  • [1] ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain
    Amann, JM
    Nip, J
    Strom, DK
    Lutterbach, B
    Harada, H
    Lenny, N
    Downing, JR
    Meyers, S
    Hiebert, SW
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (19) : 6470 - 6483
  • [2] Annunziato AT, 2000, GENE EXPRESSION, V9, P37
  • [3] Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein
    Aron, JL
    Parthun, MR
    Marcucci, G
    Kitada, S
    Mone, AP
    Davis, ME
    Shen, TS
    Murphy, T
    Wickham, J
    Kanakry, C
    Lucas, DM
    Reed, JC
    Grever, MR
    Byrd, JC
    [J]. BLOOD, 2003, 102 (02) : 652 - 658
  • [4] ASOU H, 1991, BLOOD, V77, P2031
  • [5] Histone modifications in transcriptional regulation
    Berger, SL
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 2002, 12 (02) : 142 - 148
  • [6] BISCHOFF R, 2002, HPLC BIOL MACROMOLEC, V87, P689
  • [7] Anti-tumor mechanisms of valproate: A novel role for an old drug
    Blaheta, RA
    Cinatl, J
    [J]. MEDICINAL RESEARCH REVIEWS, 2002, 22 (05) : 492 - 511
  • [8] Gene silencing -: Trans-histone regulatory pathway in chromatin
    Briggs, SD
    Xiao, TJ
    Sun, ZW
    Caldwell, JA
    Shabanowitz, J
    Hunt, DF
    Allis, CD
    Strahl, BD
    [J]. NATURE, 2002, 418 (6897) : 498 - 498
  • [9] National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
    Cheson, BD
    Bennett, JM
    Grever, M
    Kay, N
    Keating, MJ
    OBrien, S
    Rai, KR
    [J]. BLOOD, 1996, 87 (12) : 4990 - 4997
  • [10] Chromosomal mapping of core histone acetylation by immunoselection
    CraneRobinson, C
    Hebbes, TR
    Clayton, AL
    Thorne, AW
    [J]. METHODS, 1997, 12 (01) : 48 - 56